Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs PanBlok (Primary) ; AS03A; MF 59
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2017 Status changed from not yet recruiting to recruiting.
- 18 Sep 2017 New trial record